Pembrolizumab in microsatellite instability-high/mismatch repair deficient (MSI-H/dMMR) and non–MSI-H/non–dMMR advanced endometrial cancer: Phase 2 KEYNOTE-158 study results
Authors:
- David M. O'MAlleyDODavid M. O'MAlley
- Philippe A. CassierPCPhilippe A. Cassier
- Aurelien MarabelleAMAurelien Marabelle
- Aaron R. HansenAHAaron R. Hansen
- Ana De Jesus-AcostaAJAna De Jesus-Acosta
- Tamar SafraTSTamar Safra
- Antoine ItalianoAntoine Italiano
- Linda MileshkinLMLinda Mileshkin
- Lili YaoLYLili Yao
- Alexander GozmanAGAlexander Gozman
- 22 January 2025
- journal article
- research article
- Published by Elsevier in Gynecologic Oncology
- Vol. 193, 130-135
Abstract
No abstract availableKeywords
This publication has 11 references indexed in Scilit:
- Dostarlimab for Primary Advanced or Recurrent Endometrial CancerNew England Journal of Medicine, 2023
- Pembrolizumab plus Chemotherapy in Advanced Endometrial CancerNew England Journal of Medicine, 2023
- A scoping review and meta-analysis on the prevalence of pan-tumour biomarkers (dMMR, MSI, high TMB) in different solid tumoursScientific Reports, 2022
- Efficacy and safety of pembrolizumab for patients with previously treated advanced vulvar squamous cell carcinoma: Results from the phase 2 KEYNOTE-158 studyGynecologic Oncology, 2022
- Pembrolizumab in Patients With Microsatellite Instability–High Advanced Endometrial Cancer: Results From the KEYNOTE-158 StudyJournal of Clinical Oncology, 2022
- Lenvatinib plus Pembrolizumab for Advanced Endometrial CancerNew England Journal of Medicine, 2022
- Safety and antitumor activity of dostarlimab in patients with advanced or recurrent DNA mismatch repair deficient/microsatellite instability-high (dMMR/MSI-H) or proficient/stable (MMRp/MSS) endometrial cancer: interim results from GARNET—a phase I, single-arm studyJournal for ImmunoTherapy of Cancer, 2022
- Liver metastasis restrains immunotherapy efficacy via macrophage-mediated T cell eliminationNature Medicine, 2021
- Efficacy of Pembrolizumab in Patients With Noncolorectal High Microsatellite Instability/Mismatch Repair–Deficient Cancer: Results From the Phase II KEYNOTE-158 StudyJournal of Clinical Oncology, 2020
- Efficacy and Safety of Pembrolizumab in Previously Treated Advanced Cervical Cancer: Results From the Phase II KEYNOTE-158 StudyJournal of Clinical Oncology, 2019